AstraZeneca launches $1.5B savings plan to fuel pipeline growth, says workforce won't shrink
The drugmaker plans to reinvest savings in its pipeline and expects restructuring costs of up to $2 billion.
TL;DR
- AstraZeneca launched a three-year restructuring aimed at $1.5 billion in annual savings by the end of 2029.
- The company expects up to $2 billion in one-time restructuring costs and says savings will be reinvested principally in its pipeline.
- Executives expect no net workforce reduction, but did not specify which job functions will be affected.
AstraZeneca announced a three-year restructuring targeting $1.5 billion in annual savings by the end of 2029. The company said it would reinvest the savings principally in its pipeline. [1] [2] [3]
Fierce Pharma reported that the company expects up to $2 billion in one-time restructuring costs. Chief financial officer Aradhana Sarin told reporters that some positions would be eliminated while new roles are created, with no net reduction in the workforce expected. [1]
pharmaphorum identified the loss of patent protection for products including Farxiga as background to the cost program. It reported a 7% increase in third-quarter revenue to $15.19 billion. [2]
Sarin’s employment outlook is a company forecast rather than a guarantee. Fierce Pharma said executives did not specify which job functions would be affected. [1]
Why it matters
The restructuring shows how a major drugmaker plans to shift resources toward development as existing products face generic competition.
Editor's note
Savings, investment and employment outcomes are company projections. The cited STAT newsletter attributes its account of the savings plan to pharmaphorum; the independent Fierce Pharma report also covers the plan.